FOXP3 and neoplasm: The percentage of tumor-infiltrating Foxp3+CD4+ T cells was significantly decreased in tumors treated with gemcitabine, anti-CTLA-4 or the combination treatment (Figure 2F), a finding consistent with previously published data [10].